Pfizer 2010 Annual Report Download - page 115

Download and view the complete annual report

Please find page 115 of the 2010 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 120

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
Revenues by Product
Significant product revenues are as follows:
YEAR ENDED DECEMBER 31,
(MILLIONS OF DOLLARS) 2010 2009 2008
Biopharmaceutical products:
Lipitor $10,733 $11,434 $12,401
Enbrel(a), (b) 3,274 378 —
Lyrica 3,063 2,840 2,573
Prevnar/Prevenar 13(a) 2,416 ——
Celebrex 2,374 2,383 2,489
Viagra 1,928 1,892 1,934
Xalatan/Xalacom 1,749 1,737 1,745
Effexor(a) 1,718 520 —
Norvasc 1,506 1,973 2,244
Prevnar/Prevenar (7-valent)(a) 1,253 287 —
Zyvox 1,176 1,141 1,115
Sutent 1,066 964 847
Premarin family(a) 1,040 213 —
Geodon/Zeldox 1,027 1,002 1,007
Detrol/Detrol LA 1,013 1,154 1,214
Zosyn/Tazocin(a) 952 184 —
Genotropin 885 887 898
Vfend 825 798 743
Chantix/Champix 755 700 846
Protonix(a) 690 68 —
BeneFIX(a) 643 98 —
Zoloft 532 516 539
Caduet 527 548 589
Aromasin 483 483 465
Revatio 481 450 336
Pristiq(a) 466 82 —
Medrol 455 457 459
Aricept(c) 417 432 482
Zithromax/Zmax 415 430 429
Cardura 413 457 499
ReFacto AF/Xyntha(a) 404 47 —
BMP2(a) 400 81 —
Rapamune(a) 388 57 —
Fragmin 341 359 316
Tygacil(a) 324 54 —
Alliance revenues(d) 4,084 2,925 2,251
All other(e) 8,307 7,417 7,753
Total Biopharmaceutical products 58,523 45,448 44,174
Diversified products:
Animal Health(e) 3,575 2,764 2,825
Consumer Healthcare(a) 2,772 494 —
Nutrition(a) 1,867 191 —
Capsugel 752 740 767
Total Diversified products 8,966 4,189 3,592
Corporate/Other 320 372 530
Total revenues $67,809 $50,009 $48,296
(a) Legacy Wyeth products. Legacy Wyeth operations are included for a full year in 2010. In accordance with Pfizer’s domestic and international year-
ends, 2009 includes approximately two-and-a-half months of Wyeth’s U.S. operations and approximately one-and-a-half months of Wyeth’s
international operations in 2009.
(b) Outside the U.S. and Canada.
(c) Represents direct sales under license agreement with Eisai.
(d) Enbrel (in the U.S. and Canada)(a), Aricept, Exforge, Rebif and Spiriva.
(e) Includes legacy Pfizer products in 2010, 2009 and 2008. Also includes legacy Wyeth products in 2010 and, as described in note (a) above, during a
portion of 2009.
2010 Financial Report 113